I-Mab Reports Third Quarter 2024 Results
Hand-out
Press Releases
I-MAB Biopharma  
November 14, 2024

I-Mab Reports Third Quarter 2024 Results

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H

avatar profile Olean Times Herald

Olean Times Herald


Local & Social